Revenue segments as reported by the company.

Online Revenue

Wholesale Revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Marketing

Operations and support

Technology and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Hims & Hers Health

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Hims & Hers Health achieves record revenue and profitability growth

Hims & Hers Health shows strong financial performance with revenue growth and profitability milestones.
The company's focus on customer-centric strategies, brand building, and innovation drives growth.
Challenges include competition in new categories and maintaining margins on personalized products.
Opportunities lie in expanding product offerings, improving customer experience, and leveraging efficiencies.

Hims & Hers Health excels in Q1 earnings, eyes strategic growth

Hims & Hers Health delivered robust financial performance in Q1 2023, driven by revenue growth, improved margins, and disciplined expense management.
The company's strengths lie in its focus on trusted brands, innovation in product offerings, and commitment to clinical excellence, fostering consumer trust and loyalty.
While challenges like insurance reimbursement and new category entries exist, they present opportunities for strategic growth and market differentiation in the healthcare sector.

Hims & Hers Health (HIMS) reports robust Q2 earnings, eyes personalized healthcare growth

Hims & Hers Health delivered strong financial performance in Q2, driven by revenue growth, expanded gross margins, and operational efficiency. While facing short-term challenges from pricing investments, the company remains focused on long-term growth through personalized treatments and new category launches. Opportunities lie in leveraging consumer trends towards personalized healthcare and expanding product offerings.

Hims & Hers Health reports robust Q3 performance and growth opportunities

Hims & Hers Health (HIMS) showcased strong performance, innovation, and resilience in Q3, driving revenue growth, subscriber base expansion, and improved profitability.
While challenges like achieving positive net income and balancing growth with new category launches exist, the company's strategic initiatives and focus on customer value creation position it for future success.
Opportunities in the weight management category, personalized products, and efficiency gains present avenues for HIMS to capitalize on market trends and enhance its competitive edge.
With a solid financial position, a clear marketing strategy, and a commitment to customer engagement, HIMS is poised for continued growth and value creation in the healthcare sector.

Hims & Hers Health reports stellar Q4 performance and growth outlook

Hims & Hers Health delivered a strong performance in Q4 2023, with robust revenue growth, positive net income, and expanded gross margins.
The company's focus on personalized solutions, subscriber growth, and financial strength positions it well for future growth and market expansion.
While facing challenges in managing costs and margin expansion, HIMS has opportunities to drive revenue growth, enhance user experience, and offer a diverse product range.
By balancing its strengths, addressing challenges, and seizing opportunities, Hims & Hers Health is poised for continued success in the healthcare market.

Hims & Hers Health reports stellar Q1 results and eyes expansion

Hims & Hers Health's Q1 2024 performance reflects strong financial growth, driven by record subscriber numbers and revenue increase, underpinned by a strategic focus on personalized care and enhancing customer experience.
The company's strengths lie in their ability to drive consumer adoption through user-friendly solutions, capitalize on the rapid growth of the Hers segment, and maintain consumer confidence through strategic pricing initiatives.
While facing challenges in scaling operations and managing increased capital expenditures, HIMS has ample opportunities to expand their offerings, invest in new product categories, and drive further revenue growth through strategic pricing adjustments.

Hims & Hers Health posts stellar Q2 results, eyes revenue diversification

Hims & Hers Health (HIMS) reported impressive Q2 performance, with strong revenue growth and subscriber additions.
The company's strategic initiatives in weight management and sterile compounded medications position it for future success.
While facing challenges in data availability and market dynamics, Hims & Hers has opportunities for revenue diversification and enhanced customer engagement.

Hims & Hers Health (HIMS) reports stellar Q3 results and eyes growth through personalized healthcare

Hims & Hers Health's Q3 performance reflects strong revenue growth, subscriber expansion, and improved profitability, positioning the company for continued success.
While facing challenges in retention and operational efficiency, the company's strategic initiatives and market positioning offer opportunities for sustained growth and innovation.
With a focus on personalized healthcare solutions and social responsibility, Hims & Hers Health is well-positioned to capitalize on market opportunities and drive long-term value for stakeholders.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hims was founded in November 2017 after Andrew Dudum was called out by his sister for having dry skin and breakouts. After she ordered him expensive products to address his issues, Dudum realized that men don't have the same options as women when it comes to purchasing wellness products. 

Now with radiant skin, Andrew Dudum and Jack Abraham co-found HIMS as an Atomic (VC fund) portfolio company. The company initially sells hair loss treatments, biotin vitamins, shampoo, and erectile dysfunction treatments. 

The company raises $7 million in Series A from M/C Partners, SV Angel and Thrive Captial, putting its pre-money valuation at $13 million.

Hims raises $40 million in Series B led by IVP and Redpoint Ventures, putting its pre-money valuation at $160 million. 

Hims launches a women's brand, Hers. 

Hers offers telemedicine services, birth control, and non-prescription hair and skin-care products. 

The company partners with A-list couple Jennifer Lopez and Alex Rodriguez, who work with the company on the launch of new products. 

Hims raises $297 million in Series C funding led by DCM Ventures, NewView Capital, McKesson Ventures, putting its valuation at $1 billion.

Hims and Hers expands into virtual mental health services led by licensed professionals, with support groups available free of charge during the COVID-19 pandemic. 

The company now provides access to medical care and treatment for more than a dozen conditions with more than 50 products, and has facilitated 1 million medical visits through its telehealth platforms in 2019. 

Hims goes public through a merger with a blank-check company Oaktree Acquisition Corp at $1.6 billion valuation.

forhims.com/aboutus
forhims.com/investors
SEC
CNBC
Business Insider
Bloomberg
Crunchbase
Axios

Apex Technology Acquisition Corporation

Fisker Inc

Gores Holdings VI, Inc.

Golden Nugget Online Gaming

Nebula Caravel Acquisition Corp

Paysafe

Revolution Acceleration Acquisition Corp

Skillz

Following their sector-wide correction, shares in these nine SPACs and former SPACs have fallen to an attractive entry point. The post 9 SPACs to Buy After the Selloff appeared first on InvestorPlace.

9 SPACs to Buy After the Selloff

Looking for cheap telemedicine stocks on the move? Look no further.

Here's the Top Under-the-Radar Telemedicine Stock to Buy Now

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will hold its virtual annual meeting of shareholders on June 17, 2021 at 10:00 a.m. Pacific Time. A live audio webcast of the meeting will be available online at https://investors.forhims.com/. Shareholders who wish to participate can access the meeting at www.virtualshareholdermeeting.com/HIMS2021. In o

Hims & Hers Health, Inc. to Host Virtual Annual Meeting of Shareholders

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the first quarter ending March 31, 2021. “Building on our momentum from last year, Hims & Hers kicked off 2021 with a very strong first quarter, delivering robust revenue growth of 74%, gross profit growth of 95%, and ending the quarter with 391,000 subscriptions

Hims & Hers Health, Inc. Reports First Quarter 2021 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today announced that, as a result of guidance provided by the Staff of the Securities and Exchange Commission (the “SEC”) on April 12, 2021 for all SPAC-related companies regarding the accounting and reporting for their warrants, it will restate the 2020 and 2019 consolidated financial statements previou

Hims & Hers Health, Inc. Announces Response to Recent SEC Guidance Applicable to Warrants Issued by Special Purpose Acquisition Companies (“SPACs”)

Hims & Hers Inc. is the proof-of-concept that healthcare doesn't have to suck. Customers are loving it, with revenue growing from $0 to $149M in 36 months.

Hims & Hers Health Can Regrow Hair With Thicc Margins

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) are in trouble. The stock is testing critical support and if this support holds, shares may rally.

Trouble Ahead For Hims & Hers Stock?

Bumble

Roblox

Here are three companies with exciting growth stories that just went public.

3 Top Recent IPO Stocks to Buy Now

Pfizer

111 Inc - ADR

These companies are at the forefront of innovation in the healthcare sector, and their stocks are surprisingly affordable too.

3 Top Healthcare Growth Stocks to Buy for April

Ignore the near-term pullback in Hims & Hers. With its unique business model, telehealth play HIMS stock remains a potential long-term winner.

Buy Hims & Hers As It Falls Back Toward Prior Lows

Shares of the newly public company dropped on weak guidance in its fourth-quarter earnings report.

Why Hims & Hers Health Stock Was Falling Today

FedEx

There are a lot of crosscurrents in the market right now.

FedEx Signals Recovery, but This Post-Merger SPAC Led the Stock Market Lower Friday

Multi-specialty telehealth platform Hims & Hers Health, Inc. reported that revenue surged 67 percent from the fourth quarter of 2019 to the fourth quarter of 2020. “This is an organization built on solid fundamentals and favorable business characteristics and I'm incredibly confident in our ability to deliver on our vision of helping more people with a wider range […]

Hims & Hers Health, Inc Revenue Jumps 67 Pct

Hims & Hers Health Inc. (NYSE: HIMS) reported its financial results for the fiscal fourth quarter on Thursday that came in better than what analysts had anticipated, despite the ongoing Coronavirus pandemic that has so far infected more than 30 million people in the United States and caused over half a million deaths. Hims & […] The post Hims & Hers reports £3.73 million of net loss in the fourth quarter appeared first on Invezz.

Hims & Hers reports £3.73 million of net loss in the fourth quarter

Shares of Hims & Hers Health Inc. were down 8% in extended trading Thursday after the telehealth-consultation company announced fiscal fourth-quarter results. Hims & Hers reported a net loss of $5.2 million, compared with a net loss of $12.4 million in the year-ago quarter.

Hims & Hers stock dips 8% despite big hike in sales

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, today reported financial results for the fourth quarter and full year ending December 31, 2020. “We closed out this important year for Hims & Hers on a high note, meeting or exceeding the expectations for 2020 performance in our roadshow this past fall, including 80% revenue growth year-over-year and

Hims & Hers Health, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results

SAN FRANCISCO--(BUSINESS WIRE)--Andrea Perez and Ambar Bhattacharyya join Hims & Hers Board of Directors to help the company pioneer a better way for patients to access healthcare.

Hims & Hers Appoints Two New Board Members

A small company by the name of Conversion Labs (NASDAQ:CVLB) will be the eBay or Alibaba of the DTC telemedicine platforms space. The post This DTC Telemedicine Stock Has Enormous Potential Thanks to the $12 TRILLION Digital Healthcare Revolution appeared first on InvestorPlace.

This DTC Telemedicine Stock Has Enormous Potential Thanks to the $12 TRILLION Digital Healthcare Revolution

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will participate in Citi's 2021 Healthcare Services, Medtech, Tools & HCIT Virtual Conference, including a fireside chat presentation with CEO and Co-Founder, Andrew Dudum, on Thursday, February 25, 2021 at 3:20 p.m. E.T. The audio webcast and related materials will be available online at https://inv

Hims & Hers Health, Inc. to Participate in Upcoming Investor Conference

AppHarvest

Gemini Therapeutics

SPACs dominated Wall Street in 2020. The backwards IPOs of these three companies suggests that 2021 will be more of the same.

3 of the Latest Companies to Go Public Via SPACs

Telehealth is the future, and Hims & Hers looks well-positioned for that future. Growth should keep the rally in HIMS stock going.

Hims & Hers Stock Sits Where This Market Is Headed

The prospects for HIMS stock look good. The company has certainly built a robust platform.

Is Hims & Hers Health a Good Way To Play the Telehealth Megatrend?

SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (“Hims & Hers”, NYSE: HIMS), a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, will release fiscal fourth quarter and full year 2020 financial results on Thursday, March 18, 2021 after market close, with a conference call to follow at 5:00 p.m. E.T. Conference Call Details The conference call can be accessed by dialing (833) 900-2256 for U.S. participants and (236) 714-2727 for int

Hims & Hers Health, Inc. to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call

If you believe in the future of telemedicine, then keep an eye on HIMS stock. It might not be in the buy zone yet, though, so be patient.

As It Moves Goes Big on Telehealth, Hims & Hers Health Is a Buy on a Pull Back

The company has had early success in building a customer base as well as infrastructure to support their demand. HIMS offers frictionless patient to consumer experiences that are cost efficient and comprehensive.

News for Hims & Hers Health Stock (HIMS)